About Organoid Sciences
Organoid Sciences is a company based in Seongnam-si (South Korea) founded in 2019. Organoid Sciences has raised $38.96 million across 2 funding rounds from investors including Aju IB Investment, Atinum Investment and Dongwha Pharm. The company has 86 employees as of December 31, 2024. Organoid Sciences operates in a competitive market with competitors including Ensoma, Avita Medical, Organogenesis, TreeFrog Therapeutics and Pandorum, among others.
- Headquarter Seongnam-si, South Korea
- Employees 86 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Organoidsciences Ltd.
-
Annual Revenue
$1.32 M (USD)22.77as on Dec 31, 2024
-
Net Profit
-$7.63 M (USD)70.93as on Dec 31, 2024
-
EBITDA
-$7.41 M (USD)-26.36as on Dec 31, 2024
-
Total Equity Funding
$38.96 M (USD)
in 2 rounds
-
Latest Funding Round
$32.54 M (USD), Series B
Jan 13, 2022
-
Investors
Aju IB Investment
& 9 more
-
Employee Count
86
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Organoid Sciences
Organoid Sciences is a publicly listed company on the KRX with ticker symbol 476040 in South Korea, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Organoid Sciences
Organoid Sciences has successfully raised a total of $38.96M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $32.54 million completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Organoid Sciences
Organoid Sciences has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Aju IB Investment, Atinum Investment and Dongwha Pharm.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Venture capital firm investing in tech startups
|
Locked | Locked | Locked | |
|
VC firm investing in geographies such as South Korea
|
Locked | Locked | Locked |
Investor details for Organoid Sciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Organoid Sciences
Investment portfolio details for Organoid Sciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Organoid Sciences
Detailed financials for Organoid Sciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Organoid Sciences Comparisons
Peer comparison for Organoid Sciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Organoid Sciences
Organoid Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ensoma, Avita Medical, Organogenesis, TreeFrog Therapeutics and Pandorum, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of in vivo stem cell modification technologies and vector-based drug delivery tool
|
|
| Locked | Locked | Locked |
Products for regenerative and respiratory medicine are developed and distributed.
|
|
| Locked | Locked | Locked |
Regenerative therapies for wound care are developed and commercialized.
|
|
| Locked | Locked | Locked |
Developer of stem cells and organoids using proprietary technology
|
|
| Locked | Locked | Locked |
Regenerative medicine and 3D tissues are developed for therapeutic uses.
|
|
| Locked | Locked | Locked |
Reconstructive and regenerative solutions for bone conditions are developed.
|
Detailed competitors of Organoid Sciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Organoid Sciences
Complete news archive for Organoid Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Organoid Sciences
Organoid Sciences was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Organoid Sciences is headquartered in Seongnam-si, South Korea. It is registered at Seongnam-si, Gyeonggi-do, South Korea.
Jongman Yoo is the current CEO of Organoid Sciences.
Organoid Sciences is a funded company, having raised a total of $38.96M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Organoid Sciences is 86.
Annual revenue of Organoid Sciences is $1.32M as on Dec 31, 2024.
Organoid Sciences was established in 2019 and is based in Seongnam-si, South Korea. Regenerative medicines targeting various diseases are developed through cannabinoid-based approaches. A pipeline of therapeutic solutions is advanced within the biotechnology sector, with operations focused on innovative applications for health conditions. Leadership is provided by CEO Jongman Yoo, supporting ongoing research and development efforts.
Organoid Sciences's top competitors include Avita Medical, Ensoma and Organogenesis.
Yes, Organoid Sciences is publicly traded on KRX under the ticker symbol 476040.
Organoid Sciences has 10 investors. Key investors include Aju IB Investment, Atinum Investment, Dongwha Pharm, LB Investment, and Company K Partners.
The ticker symbol of Organoid Sciences is 476040 on KRX.